ATE81984T1 - Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten. - Google Patents

Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.

Info

Publication number
ATE81984T1
ATE81984T1 AT87905063T AT87905063T ATE81984T1 AT E81984 T1 ATE81984 T1 AT E81984T1 AT 87905063 T AT87905063 T AT 87905063T AT 87905063 T AT87905063 T AT 87905063T AT E81984 T1 ATE81984 T1 AT E81984T1
Authority
AT
Austria
Prior art keywords
macrophage colony
treatment
drug
manufacture
bacterial diseases
Prior art date
Application number
AT87905063T
Other languages
English (en)
Inventor
Kenneth Howard Grabstein
Philip J Morrissey
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE81984T1 publication Critical patent/ATE81984T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/145—Colony stimulating factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87905063T 1986-07-30 1987-07-20 Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten. ATE81984T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/892,123 US5162111A (en) 1986-07-30 1986-07-30 Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
PCT/US1987/001672 WO1988000832A1 (en) 1986-07-30 1987-07-20 Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP87905063A EP0317568B1 (de) 1986-07-30 1987-07-20 Verwendung von Granulozyt-Makrophagen-Kolonie Erregenden Faktor zur Herstellung eines Medikaments zur Behandlung von Bakterieller krankheiten

Publications (1)

Publication Number Publication Date
ATE81984T1 true ATE81984T1 (de) 1992-11-15

Family

ID=25399410

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87905063T ATE81984T1 (de) 1986-07-30 1987-07-20 Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.

Country Status (8)

Country Link
US (1) US5162111A (de)
EP (1) EP0317568B1 (de)
JP (1) JP2735207B2 (de)
AT (1) ATE81984T1 (de)
AU (1) AU602526B2 (de)
CA (1) CA1297789C (de)
DE (1) DE3782498T2 (de)
WO (1) WO1988000832A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795568A (en) * 1984-09-19 1998-08-18 Novartis Corporation Method of treating infectious disease with GM-CSF
US5178855A (en) * 1989-01-30 1993-01-12 Schering Corporation Treatment of luekocyte dysfunction with GM-CSF
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5681862A (en) * 1993-03-05 1997-10-28 Buckman Laboratories International, Inc. Ionene polymers as microbicides
AU699913B2 (en) * 1993-11-10 1998-12-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions and method for stimulating antibody release by B lymphocytes
JPH10505232A (ja) * 1994-08-19 1998-05-26 エンブレクス，インコーポレイテッド 鳥類骨髄単球性成長因子を用いる鳥類の処置方法
US6019965A (en) * 1994-10-24 2000-02-01 Ludwig Institute For Cancer Research Methods for treatment of pulmonary disease using GM-CSF
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
RU2121678C1 (ru) * 1997-11-11 1998-11-10 Рубальский Олег Васильевич Способ определения чувствительности микроба к антибиотику
WO2000040269A2 (en) * 1999-01-05 2000-07-13 Lee Clarence C Pharmaceutical compositions for treatment of diseased tissues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6645740B1 (en) * 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
SG143058A1 (en) * 2000-08-11 2008-06-27 Favrille Inc Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
EP3064215A1 (de) * 2002-10-16 2016-09-07 Samuel F. Hunter Verfahren zur behandlung von demyelinisierender erkrankung des zentralen nervensystems
SE0400942D0 (sv) * 2004-04-08 2004-04-08 Henrik Arnberg Composition and method
WO2006049599A1 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy for atheromatous plaques using immune modulation
US20080260650A1 (en) * 2004-10-28 2008-10-23 The General Hospital Corporation Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation
EP2094290B1 (de) * 2006-11-03 2017-07-19 Drugrecure ApS Verstärkung der pulmonalen wirtsabwehr durch verabreichung von granulozyten-makrophagen-koloniestimulierendem faktor
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
JPS59169489A (ja) * 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
JPS60209526A (ja) * 1984-04-04 1985-10-22 Denki Kagaku Kogyo Kk 高純度ｃｓｆの製造方法
JPS614506A (ja) * 1984-06-15 1986-01-10 Nitto Electric Ind Co Ltd ポリスルホン複合半透膜及びその製造方法
NZ212645A (en) * 1984-07-06 1990-02-26 Sandoz Ltd Method for producing primate granulocyte-macrophage colony stimulating factor (gm-csf)

Also Published As

Publication number Publication date
DE3782498T2 (de) 1993-03-18
AU7751987A (en) 1988-02-24
JP2735207B2 (ja) 1998-04-02
WO1988000832A1 (en) 1988-02-11
CA1297789C (en) 1992-03-24
EP0317568A4 (de) 1990-05-14
AU602526B2 (en) 1990-10-18
EP0317568B1 (de) 1992-11-04
JPH02500270A (ja) 1990-02-01
EP0317568A1 (de) 1989-05-31
DE3782498D1 (de) 1992-12-10
US5162111A (en) 1992-11-10

Similar Documents

Publication Publication Date Title
DE3782498D1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
DK382986D0 (da) Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor
DE3888064D1 (de) Niederfrequenz-Elektrotherapiegerät.
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE68905203D1 (de) Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE61227T1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
ATE74006T1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
CA2229479A1 (en) Method of promoting angiogenesis
ATE81776T1 (de) Verwendung von chinolon und naphthyridinantibiotika zur herstellung von ophthalmischen arzneimitteln.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
ATE83381T1 (de) Verwendung von rekombiniertem menschlichem alpha- interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.
Samitz et al. Electrophoretic Patterns in Psoriatic Exfoliative Erythroderma: Effects of Gamma-Globulin in Treatment of Psoriasis
RU95109228A (ru) Способ лечения трофических язв
SU1171035A1 (ru) Способ лечени сифилиса

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee